clinical trial · NCT05494697
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Pancreatic CancerRintatolimod
brief summary
The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma
started
Jun 1, 2026
primary completion
Dec 1, 2029
completion
Jan 1, 2030
last updated
Oct 14, 2025
detailed description
This is a Phase 2, randomized, open-label controlled study to evaluate the efficacy and safety of Ampligen treatment combined with standard of care (SOC) versus SOC alone following First-line therapy in subjects with locally advanced pancreatic adenocarcinoma.
official title
A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol